New Lung Cancer Treatment Hope after Major Breakthrough by Scots ScientistsByline: MATT DICKINSONDaily Mail (London)
213人 A new study has revealed a promising new treatment method for late-stage non-small cell lung cancer (NSCLC). The research, published in the Annals of Oncology, compared the efficacy and safety of two different treatments: nanoparticle polymeric micellar paclitaxel (pm-Pac) plus cisplatin ...
In lung cancer, two ADCs have been granted FDA Breakthrough Therapy Designation and are currently under evaluation (patritumab deruxtecan, telisotuzumab vedotin) and one ADC has been granted accelerated approval (Fam-trastuzumab deruxtecan-nxki (T-DXd). With hundreds of ADCs in pre-clinical ...
Although immunotherapy has achieved remarkable breakthrough in lung cancer treatment, patients with mutant p53 expressing lung cancers only show limited responses to immunotherapies. This highlights the urgent need for novel therapeutic approaches to enhance the efficacy of immunotherapies. p53 mutations often...
Cullinan Oncology announced that the FDA has granted Breakthrough Therapy Designation for CLN-081 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring epidermal growth factor (“EGFR”) exon 20 in...
How do the average direct costs for Nonsmall Cell Lung Cancer (NSCLC) patients in Italy vary by stage in the first year post-diagnosis? What improvements in treatment outcomes for early-stage Nonsmall Cell Lung Cancer (NSCLC) are anticipated due to new systemic options?
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has bee...
Dr. Barak: “We discovered that treatment in the oxygen-enriched pressure chamber reduces inflammation in the brain and leads to an increase in the expression of substances responsible for improving blood and oxygen supply to the brain, and therefore brain function. In addition, we saw a de...
, AstraZeneca, said: “Having now treated more than one million patients around the world, TAGRISSO has repeatedly transformed expectations for patients with EGFR-mutated lung cancer by not only extending survival but also showing it...